世界卫生组织东南亚区域免疫技术咨询小组第十六次会议

16–18 September 2025New Delhi, India Report of a meeting Sixteenth Meeting of the WHO South-East Asia Regional Immunization Technical Advisory GroupSEA-IMMUN-177 © World Health Organization 2025 Some rights reserved. This work is available under the Creative Commons Attribution-Noncommercial-ShareAlike 3.0 IGO licence(CC BY-NC-SA 3.0 IGO;https://creativecommons.org/licences/by-nc-sa/3.0/igo).Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, thereshould be no suggestion that WHO endorses any specific organization, products or services. The use ofthe WHO logo is not permitted. If you adapt to the work, then you must licence your work under the sameor equivalent Creative Commons licence. If you create a translation of this work, you should add thefollowing disclaimer along with the suggested citation: “This translation was not created by the WorldHealth Organization (WHO). WHO is not responsible for the content or accuracy of this translation. Theoriginal English edition shall be the binding and authentic edition”.Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization(http://www.wipo.int/amc/en/mediation/rules/). Suggested citation. Meeting of the South-East Asia Regional Working Group on Immunization. New Delhi:World Health Organization, Regional Office for South-East Asia; 2025. Licence: CC BY-NC-SA 3.0 IGO.Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submitrequests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.Third-party materials. If you wish to reuse material from this work that is attributed to a third party, suchas tables, figures or images, it is your responsibility to determine whether permission is needed for thatreuse and to obtain permission from the copyright holder. The risk of claims resulting from infringementof any third party-owned component in the work rests solely with the user.General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status ofany country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers orboundaries. Dotted and dashed lines on maps represent approximate border lines for which there maynot yet be full agreement.The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned.Errors and omissions excepted; the names of proprietary products are distinguished by initial capitalletters.All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, eitherexpressed or implied. The responsibility for the interpretation and use of the material lies with the reader.In no event shall WHO be liable for damages arising from its use.Printed in India Contents Abbreviations and acronyms ........................................................................................ 31. Introduction............................................................................................................... 62. Objectives of the meeting ......................................................................................... 83. Organization of the meeting...................................................................................... 93.1 Meeting structure ................................................................................................... 93.2 Meeting proceedings............................................................................................ 103.3 Methodology for the review of NITAG reports by SEAR-ITAG ............................. 114. Implementation update of RVIP 2022-2026............................................................ 134.1 Goal 1: Leaving “no one behind” by increasing equitable access to and use of newand underut vaccines........................................................................................... 134.2 Goal 2: Pursuing vaccine-preventable disease elimination and control goals...... 194.3 Goal 3: Reducing overall mortality and morbidity from vaccine-preventablediseases across the life-course............................................................................ 254.4 Country progress reports ..................................................................................... 285. Conclusions .......................................